🚀 VC round data is live in beta, check it out!
Akari Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Akari Therapeutics and similar public comparables like Alligator Bioscience, Oncodesign Precision Medicine, Exact Therapeutics, Cellectar Biosciences and more.
Akari Therapeutics Overview
About Akari Therapeutics
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Founded
2004
HQ
Employees
9
Website
Sectors
Financials (FY)
EV
$10M
Akari Therapeutics Financials
Akari Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($20M).
In the same fiscal year, Akari Therapeutics generated ($20M) in EBITDA losses and had net loss of ($17M).
Revenue (LTM)
Akari Therapeutics P&L
In the most recent fiscal year, Akari Therapeutics reported revenue of — and EBITDA of ($20M).
Akari Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($20M) | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($17M) | XXX | XXX | XXX |
| Net Debt | — | — | $661K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Akari Therapeutics Stock Performance
Akari Therapeutics has current market cap of $11M, and enterprise value of $10M.
Market Cap Evolution
Akari Therapeutics' stock price is $0.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $11M | 0.0% | XXX | XXX | XXX | $-0.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAkari Therapeutics Valuation Multiples
Akari Therapeutics trades at (0.5x) EV/EBITDA.
Akari Therapeutics Financial Valuation Multiples
As of March 21, 2026, Akari Therapeutics has market cap of $11M and EV of $10M.
Equity research analysts estimate Akari Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akari Therapeutics has a P/E ratio of (0.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.8x) | XXX | (0.6x) | XXX | XXX | XXX |
| P/E | (0.8x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Akari Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Akari Therapeutics Margins & Growth Rates
Akari Therapeutics' revenue in the last fiscal year grew by —.
Akari Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Akari Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncodesign Precision Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Exact Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cellectar Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Coegin Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akari Therapeutics M&A Activity
Akari Therapeutics acquired XXX companies to date.
Last acquisition by Akari Therapeutics was on XXXXXXXX, XXXXX. Akari Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Akari Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAkari Therapeutics Investment Activity
Akari Therapeutics invested in XXX companies to date.
Akari Therapeutics made its latest investment on XXXXXXXX, XXXXX. Akari Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Akari Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Akari Therapeutics
| When was Akari Therapeutics founded? | Akari Therapeutics was founded in 2004. |
| Where is Akari Therapeutics headquartered? | Akari Therapeutics is headquartered in United States. |
| How many employees does Akari Therapeutics have? | As of today, Akari Therapeutics has over 9 employees. |
| Who is the CEO of Akari Therapeutics? | Akari Therapeutics' CEO is Abizer Gaslightwala. |
| Is Akari Therapeutics publicly listed? | Yes, Akari Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Akari Therapeutics? | Akari Therapeutics trades under AKTX ticker. |
| When did Akari Therapeutics go public? | Akari Therapeutics went public in 2012. |
| Who are competitors of Akari Therapeutics? | Akari Therapeutics main competitors are Alligator Bioscience, Oncodesign Precision Medicine, Exact Therapeutics, Cellectar Biosciences. |
| What is the current market cap of Akari Therapeutics? | Akari Therapeutics' current market cap is $11M. |
| Is Akari Therapeutics profitable? | No, Akari Therapeutics is not profitable. |
| What is the current net income of Akari Therapeutics? | Akari Therapeutics' last 12 months net income is ($13M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.